DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report
Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules
October 22, 2021
BB Biotech AG publishes its interim report
BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2021, which covers the results of its business activities for the first nine months of 2021.
Based on the consolidated accounts of BB Biotech AG, net profit for the period ended September 30, 2021 amounted to CHF 141 mn (profit of CHF 26 mn in the same period 2020). In the third quarter a loss of CHF 208 mn (loss of CHF 395 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.
For further information:
22-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||BB BIOTECH AG|
|Phone:||+41 52 624 08 45|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Mailand, SIX|
|EQS News ID:||1242635|
|End of Announcement||DGAP News Service|
1242635 22-Oct-2021 CET/CEST